The industry is on target to exceed 11 billion vaccine doses by the end of 2021. But rapid action is needed to tackle manufacturing bottlenecks. Watch the video here:



At present it can take between 90 to 120 days to manufacture a single batch of COVID-19 vaccine whether mRNA, viral vector or recombinant protein. Companies are working to reduce lead times as much as possible. Read more in this blog.

When COVID hit, it felt like the whole world stopped. But cancer didn’t stop, so neither did we. Looking at what we have learnt, by continuing to work together, we can be #StrongerThanEver in the fight against cancer. Watch our video here:



The COVID-19 pandemic has hit every aspect of cancer care, putting patients at higher risk of poor outcomes. Despite the challenges, there have been some positive features of Europe’s response to the pandemic, including the adoption of digital health and greater agility in the development and approval of innovative solutions.

Stakeholders have identified six recommendations which can make cancer care delivery more resilient to disruptions and more sustainable in the post-pandemic world. Read them here.